Business
Ascendis Pharma Reports First Quarter 2026 Financial Results
- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial resul
About this update from Ascendis Pharma A/s
[{"type":"image","alt":"Ascendis Pharma","displaySize":"","headline":null,"caption":"Ascendis Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CrOiU6PjkichWByBf44j0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe","width":300,"height":100},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CrOiU6PjkichWByBf44j0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe","width":300,"height":100}},"lazy":false},{"type":"text","content":"- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA®","length":83,"tagName":"p"},{"type":"text","content":"- More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1","length":73,"tagName":"p"},{"type":"text","content":"- As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch","length":89,"tagName":"p"},{"type":"text","content":"- Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million","length":98,"tagName":"p"},{"type":"text","content":"- Conference call today at 8:00 am ET","length":37,"tagName":"p"},{"type":"text","content":"COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update.","length":198,"tagName":"p"},{"type":"text","content":"“The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH are cementing our position as a leading global biopharma,” said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma. “Our strong focus on science and making a meaningful difference for patients will continue to be the fundamental driver for our success.”","length":388,"tagName":"p"},{"type":"text","content":"Select Highlights & Anticipated 2026 Milestones","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"YORVIPATH(palopegteriparatide, developed as TransCon PTH)","length":58,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","conten...